Altimmune's weight-loss drug meets main goal in fatty liver disease trial
26/06/2025 12:25
June 26 (Reuters) - Altimmune ALT.O said on Thursday its experimental obesity drug met the main goal of a mid-stage trial studying it as a potential treatment for a fatty liver disease. (Reporting by Puyaan Singh in Bengaluru; Editing by Devika Syamnath) ((Puyaan.Singh@thomsonreuters.com;))
Recent news on Altimmune
See all newsFactbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Boehringer-Zealand's obesity drug shows promise in cutting visceral, liver fat
U.S. RESEARCH ROUNDUP-Costco Wholesale, HCA Healthcare, Micron Technology
Boehringer-Zealand drug leads to 16.6% weight loss in late-stage trial (updated)